What To Know
- At the LSI Summit, which connects early-stage medtech companies with investors, Brownlee will detail ArthroFree's advantages compared with both conventional surgical camera systems and emerging disposable systems and provide an update on marketing efforts in the year since FDA clearance on March 23rd at 11.
- By eliminating conventional camera and power cables that tether the surgeon to the surgical tower, the ArthroFree System reduces clutter in the sterile field and enhances surgeon motion and dexterity.
Lazurite® President Leah Brownlee will present at this year’s Life Science Intelligence’s Emerging MedTech Summit, March 21-23 in Dana Point, California, and Lazurite CEO and cofounder Eugene Malinskiy will present at the MedInvest Conference, March 28-29 in Palo Alto, California. The company is seeking investors for a Series B round of funding.
Lazurite is the developer of ArthroFree®, the first wireless camera system cleared by the FDA for arthroscopy and general endoscopy. By eliminating conventional camera and power cables that tether the surgeon to the surgical tower, the ArthroFree System reduces clutter in the sterile field and enhances surgeon motion and dexterity. It also eliminates camera-cable-related patient burns and OR fires. ArthroFree’s efficiencies, including faster setup and takedown times, offer projected cost-per-case savings up to 20%.
“The ArthroFree System has now been used in nearly 100 cases at facilities around the country, including NYU Langone, Hospital for Special Surgery, Rush Medical Center in Chicago, and University Hospitals in Cleveland,” Brownlee said. “More than 70 physician investors serve as internal champions for ArthroFree in more than 60 health systems that we have engaged with for product acquisition.”
At the LSI Summit, which connects early-stage medtech companies with investors, Brownlee will detail ArthroFree’s advantages compared with both conventional surgical camera systems and emerging disposable systems and provide an update on marketing efforts in the year since FDA clearance on March 23rd at 11:10 a.m.
She also will appear on the panel “What IP Issues Really Matter? Perspectives from All Sides of Diligence” on March 21st at 12:45 p.m.
The MedInvest Conference is a leading conference series in biotech and medtech. The main objective of the conference is to help early and mid-stage medtech companies and investors to partner with one another.
